12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

Leo Pharma, Virobay deal

Virobay granted LEO exclusive, worldwide rights to develop an undisclosed oral cathepsin inhibitor. The product is in preclinical...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >